Document:

EX-10.3

 Exhibit 10.3 

DEBT CONVERSION AGREEMENT 

This Debt Conversion Agreement (this “Agreement”) is dated as of November 8, 2017, among Oragenics, Inc., a Florida
corporation (the “Company”), and Intrexon Corporation (“Intrexon”). 
 RECITALS 

WHEREAS, the Company entered into a Note Purchase Agreement and executed a Promissory Note (the “Note”) to Intrexon
$2,400,000 on May 10, 2017; 
 WHEREAS, the Note provided that the unpaid amounts accrued interest at a rate of 12% per annum
and approximately $146,400 in unpaid interest has been accrued under the Note as of November 8, 2017 (the “Note Accrued Interest”); 

WHEREAS, Intrexon previously billed the Company $764,376.61 for accounts payable (the “Accounts Payable”) and
approximately $65,432.85 in unpaid interest has been accrued under the Accounts Payable as of November 8, 2017 (“Payables Accrued Interest”, together with Note Accrued Interest, the “Accrued Interest”); 

WHEREAS, the aggregate amount owed under the Accounts Payable and the Note including the Accrued Interest is $3,376,209.46 (the
“Debt”); 
 WHEREAS, the Company desires to cause the Debt to be repaid and cancelled by exchanging Series C Non-Convertible Preferred Stock of the Company (the “Series C Preferred Stock” or “Securities”) for the Debt; 

WHEREAS, Intrexon desires to acquire the Securities in exchange for the satisfaction and cancellation of the Debt; 

WHEREAS, the Company and Intrexon are executing and delivering this Agreement in reliance upon the exemption from securities
registration afforded by Section 4(2) of the Securities Act, and Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “Commission”) under the
Securities Act; 
 WHEREAS, contemporaneously with the Closing under this Agreement, the Company intends to close on a Series B
Preferred Financing with certain accredited investors (the “Series B Preferred Financing”); 
 NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the parties agree as follows: 

  
 1 

 ARTICLE I 

DEFINITIONS 
 1.1
Recitals. The foregoing recitals are true and correct and are hereby incorporated into this Agreement as if fully set forth herein. 

1.2 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.2: 
 “Affiliate” means any Person that, directly or indirectly through
one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 144 under the Securities Act. With respect to Intrexon, any investment fund or managed account that
is managed on a discretionary basis by the same investment manager as Intrexon will be deemed to be an Affiliate of Intrexon. 

“Business Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. 

“Certificate of Designation” means the Certificate of Designation of the Series C Preferred Stock to be filed prior to the
Closing by the Company with the Secretary of State of Florida in the form of Exhibit A attached hereto. 

“Closing” means the closing of the conversion of the Debt into shares of Series C Preferred Stock contemplated hereby. 

“Closing Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the
applicable parties thereto, and all conditions precedent to (i) Intrexon’s obligations to convert the Debt and (ii) the Company’s obligations to deliver the Securities issuable at the Closing, in each case, have been satisfied or
waived. 
 “Commission” means the Securities and Exchange Commission. 

“Common Stock” means the Common Stock of the Company, par value $0.001 per share, and any other class of securities into
which such securities may hereafter be reclassified or changed into. 
 “Common Stock Equivalents” means any securities of
the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into
or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 
 “Company Counsel”
means Shumaker, Loop & Kendrick, LLP, with offices located at 101 E. Kennedy Blvd. Suite 2800, Tampa, Florida 33602. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 “GAAP” shall have the meaning ascribed to such term in Section 3.1(e). 

“Intellectual Property” shall have the meaning ascribed to such term in Section 3.1(o). 

  
 2 

 “Legend Removal Date” shall have the meaning ascribed to such term in
Section 4.1(c). 
 “Liens” means a lien, charge, security interest, encumbrance, right of first refusal, preemptive
right or other restriction. 
 “Material Adverse Effect” shall have the meaning assigned to such term in
Section 3.1(a). 
 “Per Share Exchange Price” equals $33,847.9874. 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or
partial proceeding, such as a deposition), whether commenced or threatened. 
 “Rule 144” means Rule 144 promulgated by the
Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“SEC Documents” shall have the meaning ascribed to such term in Section 3.1(e). 

“Securities” means the Series C Preferred Stock. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

“Series C Preferred Stock” has the meaning set forth in the recitals. 

“Shares” means the shares of Series C Preferred Stock issued or issuable to Intrexon pursuant to this Agreement. 

“Short Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation
SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker dealers or foreign
regulated brokers. 
 “Subsidiary” means any subsidiary of the Company as set forth in the SEC Documents. 

“Trading Day” means a day on which the Common Stock is traded on a Trading Market. 

“Trading Market” means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the
date in question: the American Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the OTC Bulletin Board. 

  
 3 

 “Transaction Documents” means this Agreement, Voting Agreement, ECC Amendments,
and Certificate of Designation. 
 “Transfer Agent” means Continental Stock Transfer and Trust Company, and any successor
transfer agent of the Company. 
 “Voting Agreement” means the written agreement, in the form of Exhibit C
attached hereto, of Intrexon Corporation, Harvest Intrexon Enterprise Fund I (AI), L.P., Harvest Intrexon Enterprise Fund I, L.P., the Koski Family Limited Partnership, MSD Credit Opportunity Master Fund, L.P., and their respective affiliates, such
persons who have voting control as of the date hereof, amounting to, in the aggregate, a majority of the issued and outstanding Common Stock. 

ARTICLE II 
 DEBT
CONVERSION 
 2.1 Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially
concurrent with the execution and delivery of this Agreement by the parties hereto, Intrexon hereby agrees to exchange the Debt for the issuance of One Hundred (100) shares of Series C Preferred Stock at the Per Share Exchange Price by the
Company to Intrexon having a stated value equal to the amount of the Debt (the “Conversion Securities”). Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3 applicable to the Closing, the Closing
shall occur at the offices of Company Counsel or such other location as the parties shall mutually agree. When issued to Intrexon at the Closing, the Conversion Securities will be deemed to have been issued in full satisfaction and payment of the
Debt owed by the Company to Intrexon. 
 2.2 Deliveries. 

(a) On or prior to the Closing Date (unless otherwise indicated below), the Company shall deliver or cause to be delivered to Intrexon the
following: 
 (i), this Agreement duly executed by the Company; 

(ii) a legal opinion of Company Counsel, substantially in the form of Exhibit B attached hereto; 

(iii) an irrevocable letter of instruction to the transfer agent to issue book entry evidencing 100 shares of Series C Preferred Stock
registered in the name of Intrexon and evidence of the filing and acceptance of the Certificate of Designation from the Secretary of State of Florida; 

(iv) the Voting Agreement duly executed by the Series B Preferred Financing participants; 

(v) the Amendment to the June 2012 Stock Issuance Agreement duly executed by the Company; 

(vi) the Second Amendment to the June 2012 Exclusive Channel Agreement duly executed by the Company; 

(vii) the Second Amendment to the June 2015 Stock Issuance Agreement duly executed by the Company; and 

  
 4 

 (viii) the Second Amendment to the June 2015 Exclusive Channel Agreement duly executed by the
Company. 
 (b) On or prior to the Closing Date, Intrexon shall deliver or cause to be delivered to the Company the following: 

(i) this Agreement duly executed by Intrexon; 

(ii) the original Note marked “cancelled”; 

(iii) the Voting Agreement duly executed by Intrexon; 

(iv) the Amendment to the June 2012 Stock Issuance Agreement duly executed by Intrexon; 

(v) the Second Amendment to the June 2012 Exclusive Channel Agreement duly executed by Intrexon; 

(vi) the Second Amendment to the June 2015 Stock Issuance Agreement duly executed by Intrexon; and 

(vii) the Second Amendment to the June 2015 Exclusive Channel Agreement duly executed by Intrexon and Intrexon Actobiotics NV. 

2.3 Closing Conditions. 

(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met or waived by the
Company: 
 (i) the accuracy in all material respects when made and on the Closing Date of the representations and warranties of Intrexon
contained herein (except with respect to representations and warranties which relate to a specific date, in which case such representations and warranties shall continue to be materially accurate as of such date); 

(ii) all obligations, covenants and agreements of Intrexon required to be performed at or prior to the applicable Closing Date shall have been
performed; 
 (iii) the delivery by Intrexon of the items set forth in Section 2.2(b) of this Agreement; 

(iv) no statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by
any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents; 

(v) the simultaneous closing of the Series B Preferred Financing; and 

(vi) the Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary for
consummation of the issuance of the Shares, all of which shall be and remain so long as necessary in full force and effect. 

  
 5 

 (b) The obligations of Intrexon hereunder in connection with the Closing are subject to the
following conditions being met or waived by Intrexon as to itself: 
 (i) the accuracy in all material respects on the Closing Date of the
representations and warranties of the Company contained herein (except with respect to representations and warranties which relate to a specific date, in which case such representations and warranties shall continue to be materially accurate as of
such date); 
 (ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall
have been performed; 
 (iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement and a certificate,
dated as of the Closing Date and signed by its Chief Executive Officer or its Chief Financial Officer, certifying to the fulfillment of the conditions specified in Sections 2.3(b)(i) and (ii); 

(iv) on the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company’s principal Trading
Market (except for any suspension of trading of limited duration agreed to by the Company, which suspension shall be terminated prior to the applicable Closing Date), and, at any time prior to the Closing Date, trading in securities generally as
reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been
declared either by the United States or New York State authorities; 
 (v) no statute, rule, regulation, executive order, decree, ruling or
injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents; 

(vi) the simultaneous closing of the Series B Preferred Financing; and 

(vii) the Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary for
consummation of the purchase and sale of the Shares, all of which shall be and remain so long as necessary in full force and effect. 

ARTICLE III 

REPRESENTATIONS AND WARRANTIES 

3.1 Representations and Warranties of the Company. Except as set forth in the SEC Documents, the Company hereby makes the following
representations and warranties to Intrexon as of the Closing Date: 
 (a) Organization, Good Standing and Power. The Company is a
corporation duly incorporated, validly existing and in good standing under the laws of the State of Florida and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its business as it is now being
conducted and as described in the reports filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, 

  
 6 

 
since the end of its most recently completed fiscal year through the date hereof, including, without limitation, its most recent report on Form 10-Q. The
Company does not have any material subsidiaries. The Company is qualified to do business as a foreign corporation and is in good standing in every jurisdiction in which the nature of the business conducted or property owned by it makes such
qualification necessary, except for any jurisdiction(s) (alone or in the aggregate) in which the failure to be so qualified will not have a Material Adverse Effect. For the purposes of this Agreement, “Material Adverse Effect” means
any effect on the business, operations, properties or financial condition of the Company that is material and adverse to the Company, taken as a whole, and any condition, circumstance or situation that would prohibit the Company from entering into
and performing any of its obligations hereunder. 
 (b) Authorization; Enforcement. The Company has the requisite corporate power and
authority to enter into and perform the Transaction Documents and to issue the Shares in accordance with the terms hereof. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby have been duly and validly authorized by all necessary corporate action, and no further consent or authorization of the Company, its board of directors or stockholders is required. When executed and delivered by the
Company, the Transaction Documents shall constitute a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, reorganization,
moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application. 

(c) Issuance of Shares. The Shares to be issued and sold hereunder have been duly authorized by all necessary corporate action and, when
issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable. In addition, the Shares will be free and clear of all liens, claims, charges, security interests or agreements, pledges, assignments, covenants,
restrictions or other encumbrances created by, or imposed by, the Company (collectively, “Encumbrances”) and rights of refusal of any kind imposed by the Company (other than restrictions on transfer under applicable securities laws)
and the holder of such Shares shall be entitled to all rights accorded to a holder of Common Stock. The Company has not issued any shares of Common Stock, shares of Series A preferred stock, options or warrants since its most recent report on Form 10-Q. 
 (d) No Conflicts; Governmental Approvals. The execution, delivery and performance of the
Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not (i) violate any provision of the Company’s Articles of Incorporation or Bylaws, each as amended to date,
(ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, mortgage,
deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which the Company is a party or by which the Company’s properties or assets are bound, or (iii) result in a violation of any federal, state, local
or foreign statute, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable to the Company or by which any property or asset of the Company is bound or affected, except for such conflicts,
defaults, terminations, amendments, acceleration, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect. The Company is not required under federal, state, foreign or local law, rule or

  
 7 

 
regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its
obligations under this Agreement or issue and sell the Shares in accordance with the terms hereof (other than any filings, consents and approvals which may be required to be made by the Company under applicable state and federal securities laws,
rules or regulations prior to or subsequent to Closing). 
 (e) SEC Documents, Financial Statements. The Common Stock of the Company
is registered pursuant to Section 12(g) of the Exchange Act. During the year preceding this Agreement, the Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by it with the Commission
pursuant to the reporting requirements of the Exchange Act (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein being collectively referred to as the “SEC Documents”). At the times
of their respective filing, all such reports, schedules, forms, statements and other documents complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the Commission promulgated thereunder. At the
times of their respective filings, such reports, schedules, forms, statements and other documents did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the SEC Documents complied in all material respects with applicable
accounting requirements and the published rules and regulations of the Commission or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance with United States generally accepted
accounting principles applied on a consistent basis (“GAAP”) during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim
statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the consolidated financial position of the Company as of the dates thereof and the results of operations
and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). 

(f) Accountants. Mayer Hoffman McCann P.C. whose report on the financial statements of the Company is filed with the Commission in the
Company’s Annual Report on Form 10-K for the year ended December 31, 2016, were, at the time such report was issued, independent registered public accountants as required by the Securities Act. 

(g) Internal Controls. The Company has established and maintains a system of internal accounting controls sufficient to provide
reasonable assurances that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with
generally accepted accounting principles in the United States and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded
accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 

  
 8 

 (h) Disclosure Controls. The Company has established and maintains disclosure controls and
procedures (as such term is defined in Rules 13a-15 and 15d-15 under the Exchange Act). Since the date of the most recent evaluation of such disclosure controls and
procedures, there have been no significant changes in internal controls or in other factors that could significantly affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses. The
Company is in compliance in all material respects with all provisions currently in effect and applicable to the Company of the Sarbanes-Oxley Act of 2002, and all rules and regulations promulgated thereunder or implementing the provisions thereof.

 (i) No Material Adverse Change. Except as disclosed in the SEC Documents, since June 30, 2017, the Company has not
(i) experienced or suffered any Material Adverse Effect, (ii) incurred any material liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) other
than those incurred in the ordinary course of the Company’s business or (iii) declared, made or paid any dividend or distribution of any kind on its capital stock. 

(j) No Undisclosed Events or Circumstances. Except as disclosed in the SEC Documents, and except for the consummation of the
transactions contemplated herein, since June 30, 2017, to the Company’s knowledge, no event or circumstance has occurred or exists with respect to the Company or its businesses, properties, prospects, operations or financial condition,
which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed. 

(k) Litigation. No action, suit, proceeding or investigation is currently pending or, to the knowledge of the Company, has been
threatened in writing against the Company that: (i) concerns or questions the validity of this Agreement; (ii) concerns or questions the right of the Company to enter into this Agreement; or (iii) is reasonably likely to have a
Material Adverse Effect. The Company is neither a party to nor subject to the provisions of any material order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or
investigation by the Company currently pending or that the Company intends to initiate that would have a Material Adverse Effect. 
 (l)
Compliance. Except for defaults or violations which are not reasonably likely to have a Material Adverse Effect, the Company is not (i) in default under or in violation of (and no event has occurred that has not been waived that, with
notice or lapse of time or both, would result in a default by the Company under), nor has the Company received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other
agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body, or
(iii) is or has been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws, applicable to its business. 

(m) Intellectual Property 

(a) To the best of its knowledge, the Company has entered into agreements with each of its current and former officers, employees and
consultants involved in research and development work, including development of the Company’s products and technology providing the Company, to the extent permitted by law, with title and ownership to patents, patent applications, trade secrets
and inventions conceived, developed, reduced to practice by such person, solely or jointly with other of such persons, during the period of employment by the Company except where the failure to have entered into such an agreement would not have a
Material Adverse Effect. The Company is not aware that any of its employees or consultants is in material violation thereof. 
  

  
 9 

 (b) To the Company’s knowledge, the Company owns or possesses adequate rights to use all
trademarks, service marks, trade names, domain names, copyrights, patents, patent applications, inventions, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures),
and other intellectual property rights (“Intellectual Property”) as are necessary for the conduct of its business as described in the SEC Documents. Except as described in the SEC Documents, (i) to the knowledge of the Company,
there is no infringement, misappropriation or violation by third parties of any such Intellectual Property; (ii) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others against the Company
challenging the Company’s rights in or to any such Intellectual Property; (iii) the Intellectual Property owned by the Company and, to the knowledge of the Company, the Intellectual Property licensed to the Company has not been adjudged
invalid or unenforceable by a court of competent jurisdiction or applicable government agency, in whole or in part, and there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the
validity or scope of any such Intellectual Property; (iv) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others against the Company that the Company infringes, misappropriates or
otherwise violates any Intellectual Property or other proprietary rights of others, and the Company has not received any written notice of such claim; and (v) to the Company’s knowledge, no employee of the Company is the subject of any
claim or proceeding involving a violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement,
non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment with the Company or
actions undertaken by the employee while employed with the Company, in each of (i) through (v), for any instances which would not, individually or in the aggregate, result in a Material Adverse Effect. 

(n) FDA Compliance. 
 (a)
Except as described in the SEC Documents, the Company: (i) is in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product that is under development, manufactured or distributed by the Company (“Applicable Laws”); (ii) has not received any FDA Form
483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory
authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws
(“Authorizations”), which would not, individually or in the aggregate, result in a Material Adverse Effect; (iii) possesses all material Authorizations necessary for the operation of its business as described in the SEC
Documents and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations; and (iv) since January 1, 2017: (A) has not received notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other 

  
 10 

 
federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or
Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding;
(B) has not received notice that the FDA or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has
no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is considering such action; (C) has filed, obtained, maintained or submitted all material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (D) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated,
conducted or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, “dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product
defect or violation and, to the Company’s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action. 

(b) Since January 1, 2017, and except to the extent disclosed in the SEC Documents, the Company has not received any notices or
correspondence from the FDA or any other federal, state, local or foreign governmental or regulatory authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on
behalf of the Company. 
 (o) General Healthcare Regulatory Compliance. 

(a) As used in this subsection: 

(i) “Governmental Entity” means any national, federal, state, county, municipal, local or foreign government, or any
political subdivision, court, body, agency or regulatory authority thereof, and any Person exercising executive, legislative, judicial, regulatory, taxing or administrative functions of or pertaining to any of the foregoing. 

(ii) “Law” means any federal, state, local, national or foreign law, statute, code, ordinance, rule, regulation, order,
judgment, writ, stipulation, award, injunction, decree or arbitration award or finding. 
 (b) The Company has not committed any act, made
any statement or failed to make any statement that would reasonably be expected to provide a basis for the FDA or any other Governmental Entity to invoke its policy with respect to “Fraud, Untrue Statements of Material Facts, Bribery, and
Illegal Gratuities”, or similar policies, set forth in any applicable Laws. Neither the Company, nor, to the knowledge of the Company, any of its officers, key employees or agents has been convicted of any crime or engaged in any conduct that
has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation, 21 U.S.C. Section 335a. No claims, actions, proceedings or investigations that would reasonably be expected to result in
such a material debarment or exclusion are pending, or to the knowledge of the Company, threatened, against the Company or any of its respective officers, employees or agents. 

 

  
 11 

 (c) Each of the Company and, to its knowledge, its directors, officers, employees, and agents
(while acting in such capacity) is, and at all times has been, in material compliance with all health care Laws applicable to the Company or by which any of its properties, businesses, products or other assets is bound or affected, including,
without limitation, the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the Anti-Inducement Law (42 U.S.C. § 1320a-7a(a)(5)), the civil False
Claims Act (31 U.S.C. §§ 3729 et seq.), the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et
seq.), the exclusion laws (42 U.S.C. § 1320a-7), the Food Drug and Cosmetic Act (21 U.S.C. §§ 301 et seq.) (collectively, “Health Care Laws”). The Company has not received any
notification, correspondence or any other written or oral communication from any Governmental Entity, including, without limitation, the FDA, the Centers for Medicare and Medicaid Services, and the Department of Health and Human Services Office of
Inspector General, of potential or actual material non-compliance by, or liability of, the Company under any Health Care Laws. 

(d) The Company is not a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar
agreements with or imposed by any Governmental Entity. 
 (p) Application of Takeover Protections. The issuance of the Shares
hereunder and Intrexon’s ownership thereof is not prohibited by the business combination statutes of the state of Florida. The Company has not adopted any stockholder rights plan, “poison pill” or similar arrangement that would
trigger any right, obligation or event as a result of the issuance of such Shares and Intrexon’s ownership of such Shares and there are no similar anti-takeover provisions under the Company’s charter documents. 

(q) Listing and Maintenance Requirements. The Company is in compliance with the requirements of the Trading Market for continued trading
of the Common Stock pursuant thereto. The issuance and sale of the Shares hereunder does not contravene the rules and regulations of the Trading Market. 

(r) Private Placement. Neither the Company nor its Affiliates, nor any Person acting on its or their behalf, (i) has engaged in any
form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer or sale of the Shares hereunder, (ii) has, directly or indirectly, made any offers or sales of any
security or solicited any offers to buy any security, under any circumstances that would require registration of the sale and issuance by the Company of the Shares under the Securities Act or (iii) has issued any shares of Common Stock or
shares of any series of preferred stock or other securities or instruments convertible into, exchangeable for or otherwise entitling the holder thereof to acquire shares of Common Stock which would be integrated with the sale of the Shares to
Intrexon for purposes of the Securities Act or of any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of the
Company are listed or designated, nor will the Company or any of its subsidiaries or affiliates take any action or steps that would require registration of any of the Shares under the Securities Act or cause the offering of the shares to be
integrated with other offerings. Assuming the accuracy of the representations and warranties of Intrexon, the offer and issuance of the Shares by the Company to Intrexon pursuant to this Agreement will be exempt from the registration requirements of
the Securities Act. 
  

  
 12 

 (s) No Manipulation of Stock. The Company has not taken, and has no plans to take,
in violation of applicable law, any action outside the ordinary course of business designed to, or that might reasonably be expected to, cause or result in unlawful manipulation of the price of the Common Stock. 

(t) Brokers. Other than Dawson James, neither the Company nor any of the officers, directors or employees of the Company has employed
any broker or finder in connection with the transaction contemplated by this Agreement. The Company shall indemnify Intrexon from and against any broker’s, finder’s or agent’s fees for which the Company is responsible. 

(u) Solvency. Based on the financial condition of the Company as of the Closing Dates, after giving effect to the receipt by the Company
of the proceeds from the sale of the Shares hereunder, (i) the fair saleable value of the Company’s assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities
(including known contingent liabilities) as they mature; (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking
into account the particular capital requirements of the business conducted by the Company, and projected capital requirements and capital availability thereof; and (iii) the current cash flow of the Company, together with the proceeds the
Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The
Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). Assuming the Closing occurs, the Company has no knowledge of
any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. 

(v) Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of
the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or
domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of
which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 

(w) Voting Agreement. The signatories to the Voting Agreement have voting control with respect to the Company as of the date hereof,
amounting to, in the aggregate, a majority of the issued and outstanding Common Stock. 
 3.2 Representations and Warranties of
Intrexon. Intrexon hereby represents and warrants to the Company as follows (as of the Closing Date, unless otherwise noted below): 

  
 13 

 (a) Authority. The execution, delivery and performance by Intrexon of the transactions
contemplated by this Agreement have been duly authorized by all necessary corporate or similar action on the part of Intrexon. Each Transaction Document to which it is a party has been duly executed by Intrexon, and when delivered by Intrexon in
accordance with the terms hereof, will constitute the valid and legally binding obligation of Intrexon, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other
equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 
 (b) Own
Account. Intrexon understands that the Shares are “restricted securities” and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Shares as principal for its own account and not
with a view to or for distributing or reselling such Shares or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Shares in violation of the Securities Act
or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Shares (this representation and warranty not limiting Intrexon’s right
to sell the Shares pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws) in violation of the Securities Act or any applicable state securities law. Intrexon is acquiring the Shares
hereunder in the ordinary course of its business. Intrexon understands that it may not be able to sell any of the Shares without prior registration under the Securities Act or the existence of an exemption from such registration requirement. 

(c) No Conflicts. The execution, delivery and performance by Intrexon of this Agreement and the consummation by Intrexon of the
transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of Intrexon, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a
default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which Intrexon is a party, or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including federal and state securities laws) applicable to Intrexon, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate,
reasonably be expected to have a material adverse effect on the ability of Intrexon to perform its obligations hereunder. 
 (d) Purchaser
Status. At the time Intrexon was offered the Shares, it was, and at the date hereof is, an “accredited investor” as defined in Rule 501 under the Securities Act. Investor is not a registered broker dealer registered under
Section 15(a) of the Exchange Act, or a member of the Financial Industry Regulatory Authority Inc. (“FINRA”), or an entity engaged in the business of being a broker-dealer. 

(e) Experience of Intrexon. Intrexon, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated the merits and risks of such investment. Intrexon is able to bear the economic risk
of an investment in the Shares and, at the present time, is able to afford a complete loss of such investment. Intrexon acknowledges that it has not received any legal or tax advice from the Company or any of its representatives with respect the
transactions contemplated hereby. 
  

  
 14 

 (f) No Trading Market for Shares. Intrexon understands and acknowledges that there is no
market for the Shares and that none is likely to develop and that the Shares will not be listed on any Trading Market. 
 (g) General
Solicitation. Intrexon is not purchasing the Shares as a result of any advertisement, article, notice or other communication regarding the Shares published in any newspaper, magazine or similar media or broadcast over television or radio or
presented at any seminar or any other general solicitation or general advertisement. 
 (h) Access to Information. Intrexon
acknowledges that it has had the opportunity to review any Company information and business updates requested by Intrexon and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers
from, representatives of the Company concerning the terms and conditions of the offering of the Shares and the merits and risks of investing in the Shares and; (ii) access to information about the Company and its financial condition, results of
operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort
or expense that is necessary to make an informed investment decision with respect to the investment. Intrexon has sought such accounting, legal and tax advice as it has considered necessary to make an informed decision with respect to its
acquisition of the Shares. Intrexon also acknowledges that it has had the opportunity to review the Series B Preferred Financing terms and transaction documents. 

(i) Certain Trading Activities. As of the date hereof, other than with respect to the transactions contemplated herein, since the time
that Intrexon was first contacted by the Company or any other Person regarding the transactions contemplated hereby, neither Intrexon nor any Affiliate of Intrexon which (x) had knowledge of the transactions contemplated hereby, (y) has or
shares discretion relating to Intrexon’s investments or trading or information concerning Intrexon’s investments, including in respect of the Shares, and (z) is subject to Intrexon’s review or input concerning such
Affiliate’s investments or trading (collectively, “Trading Affiliates”) has directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with Intrexon or Trading Affiliate, effected or agreed
to effect any purchases or sales of the securities of the Company (including, without limitation, any Short Sales involving the Company’s securities). Notwithstanding the foregoing, in the case of a Intrexon and/or Trading Affiliate that is,
individually or collectively, a multi-managed investment bank or vehicle whereby separate portfolio managers manage separate portions of Intrexon or Trading Affiliate’s assets and the portfolio managers have no direct knowledge of the
investment decisions made by the portfolio managers managing other portions of Intrexon’s or Trading Affiliate’s assets, the representation set forth above shall apply only with respect to the portion of assets managed by the portfolio
manager that have knowledge about the financing transaction contemplated by this Agreement. Other than to other Persons party to this Agreement, their affiliates and each of their respective professional advisors, Intrexon maintained the
confidentiality of all non-public information disclosed to it in connection with the transactions contemplated hereby (including the existence and terms of such transactions) at all times prior to the issuance
of the Press Release (as defined below). 

  
 15 

 (j) Brokers and Finders. No Person will have, as a result of the transactions contemplated
by this Agreement, any valid right, interest or claim against or upon the Company or Intrexon for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of Intrexon. 

(k) Independent Investment Decision. Intrexon has independently evaluated the merits of its decision to purchase Shares pursuant to the
Transaction Documents, and Intrexon confirms that it has not relied on the advice of any other business and/or legal counsel in making such decision. Intrexon understands that nothing in this Agreement or any other materials presented by or on
behalf of the Company to Intrexon in connection with the purchase of the Shares constitutes legal, tax or investment advice. Intrexon has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its purchase of the Shares. 
 (l) No Governmental Review. Intrexon understands that no United States
federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Shares or the fairness or suitability of the investment in the Shares nor have such authorities passed upon or
endorsed the merits of the offering of the Shares. 
 (m) Residency. Intrexon’s residence (if an individual) or office in which
its investment decision with respect to the Shares was made (if an entity) are located at the address immediately below Intrexon’s name on its signature page hereto. 

(n) Acknowledgment. Intrexon acknowledges and agrees that Intrexon has reviewed and considered prior to entering this Agreement the more
detailed information about the Company and the risk factors that may affect the realization of forward-looking statements set forth in the Company’s filings with the SEC, including its Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q filed with the SEC. 

The Company and Intrexon acknowledge and agree that no party to this Agreement has made or makes any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in this Article III and the Transaction Documents. 

ARTICLE IV 
 OTHER
AGREEMENTS OF THE PARTIES 
 4.1 Transfer Restrictions. 

(a) The Securities may only be disposed of in compliance with state and federal securities laws, including the requirement not to trade in the
Securities while in possession of material non-public information. In connection with any transfer of Shares other than pursuant to an effective registration statement, to the Company or to an Affiliate of
Intrexon or in connection with a pledge as contemplated in Section 4.1(c), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the
form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Shares under the Securities Act. As a condition of transfer, any such transferee
shall agree in writing to be bound by the terms of this Agreement and shall have the rights of Intrexon under this Agreement. 

  
 16 

 (b) Intrexon agrees to the imprinting, so long as is required by this Section 4.1, of a
legend on any of the Securities in the following form: 
 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED
BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES. 

(c) The Company acknowledges and agrees that Intrexon may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this
Agreement and, if required under the terms of such arrangement, Intrexon may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of
legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At Intrexon’s expense, the Company will execute and deliver such reasonable documentation as
a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities. 
 (d) Intrexon
agrees that the removal of the restrictive legend from certificates representing Securities as set forth in this Section 4.1 is predicated upon the Company’s reliance that Intrexon will sell any Securities pursuant to either the
registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance with the
plan of distribution set forth therein. 

  
 17 

 4.2 Furnishing of Information. For a period of one year after the date of this Agreement,
the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act. During this one-year period, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to Intrexon and make publicly available in accordance with Rule 144 such information as is
required for Intrexon to sell the Shares under Rule 144. The Company further covenants that it will take such further action as any holder of Shares may reasonably request, to the extent required from time to time to enable such Person to sell such
Shares without registration under the Securities Act within the requirements of the exemption provided by Rule 144. 
 4.3
Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that could reasonably be expected to be integrated with
the offer or sale of the Shares in a manner that would require the registration under the Securities Act of the sale of the Shares to Intrexon or that would be integrated with the offer or sale of the Shares for purposes of the rules and regulations
of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction. 

4.4 Securities Laws Disclosure; Publicity. On or before 9:00 a.m., New York City time, on the Business Day immediately following the
date hereof, the Company shall issue a press release (the “Press Release”) reasonably acceptable to Intrexon disclosing all material terms of the transactions contemplated hereby. On or before 5:30 p.m., New York City time, on the
fourth Trading Day immediately following the execution of this Agreement, the Company will file a Current Report on Form 8-K with the Commission describing the terms of the Transaction Documents (and including
as exhibits to such Current Report on Form 8-K the material Transaction Documents (including, without limitation, this Agreement)). Notwithstanding the foregoing, the Company shall not publicly disclose the
name of Intrexon or an Affiliate of Intrexon, or include the name of Intrexon or an Affiliate of Intrexon in any press release or filing with the Commission (other than the Registration Statement) or any regulatory agency or Trading Market, without
the prior written consent of Intrexon, except (i) as required by federal securities law in connection with the filing of final Transaction Documents (including signature pages thereto) with the Commission and (ii) to the extent such
disclosure is required by law, request of the Staff of the Commission or Trading Market regulations, in which case the Company shall provide Intrexon with prior written notice of such disclosure permitted under this subclause (ii). 

4.5 Indemnification of Intrexon. 

(a) The Company will indemnify and hold Intrexon and its directors, officers, stockholders, members, partners, employees and agents (and any
other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls Intrexon (within the meaning of Section 15 of the Securities Act and
Section 20 of the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title) of such controlling person (each, a “Purchaser Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,

  
 18 

 
amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any Purchaser Party may suffer or incur (i) as a result of any breach of any of
the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (ii) arising out of, in connection with, or as a result of the execution or delivery of this Agreement, any
other Transaction Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or
thereby. The Company will not be liable to any Purchaser Party under this Agreement to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations,
warranties, covenants or agreements made by Purchaser Party in this Agreement or in the other Transaction Documents. 
 (b) Promptly after
receipt by any Person (the “Indemnified Person”) of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding or investigation in respect of which indemnity
may be sought pursuant to Section 4.5(a), such Indemnified Person shall promptly notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified
Person, and shall assume the payment of all fees and expenses; provided, however, that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations hereunder except to the extent that the Company is
actually and materially and adversely prejudiced by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such
Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention of such counsel; (ii) the Company shall have failed promptly to assume the defense of such proceeding and to employ counsel
reasonably satisfactory to such Indemnified Person in such proceeding; or (iii) in the reasonable judgment of counsel to such Indemnified Person, representation of both parties by the same counsel would be inappropriate due to actual or
potential differing interests between them. The Company shall not be liable for any settlement of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned. Without the prior
written consent of the Indemnified Person, which consent shall not be unreasonably withheld, delayed or conditioned, the Company shall not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or
could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified Person from all liability arising out of such proceeding, does not admit
liability on the part of or attribute fault to any Indemnified Person and contains a provision requiring confidentiality with respect to the facts and circumstances of the dispute and of the existence and amount of the settlement. 

4.6 Reservation of Preferred Stock. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep
available at all times, a sufficient number of shares of Series C Preferred Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement. 

4.7 Waiver and Consent. Intrexon elects not to participate in the Series B Preferred Financing and in connection therewith
(a) waives any and all contractual rights to participate in the Series B Financing and (b) consents to the registration rights being granted to the investors in the Series B Financing. 

  
 19 

 4.8 Confidentiality After The Date Hereof. Intrexon covenants that until such time as the
transactions contemplated by this Agreement and such other material non-public information related to the Company in possession of Intrexon are publicly disclosed by the Company as described in
Section 4.4, Intrexon will maintain the confidentiality of all non-public information disclosed to it in connection with the transactions contemplated hereby (including the existence and terms of such
transactions). 
 4.9 Delivery of Shares After Closing. The Company shall deliver, or cause to be delivered, the respective Shares
purchased by Intrexon to Intrexon within three Trading Days of the Closing Date (unless Intrexon has specified to the Company at the time of execution of this Agreement that it shall settle “delivery versus payment” in which case such
Shares shall be delivered on or prior to the Closing Date). 
 4.10 Form D; Blue Sky Filings. The Company agrees to timely file a Form
D with respect to the Shares as required under Regulation D and to provide a copy thereof, promptly upon request of Intrexon. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption
for, or to qualify the Shares for, sale to Intrexon at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request of Intrexon. 

4.12 Use of Proceeds. The Company intends to use the net proceeds of this offering after payment of the expenses of the offering for the
funding of its AG013 research and clinical trials and for general corporate purposes, including working capital and shall not use such proceeds for the satisfaction of any portion of the Company’s debt (other than trade payables in the ordinary
course of the Company’s business and prior practices), or to redeem any Common Stock or Common Stock Equivalents. 
 4.13 Prepaid
Invoice Amount. The Per Share Exchange Price reflects an overpayment of the Debt equal to $8,589.28. The Company and Intrexon agree that such amount shall be treated as a prepaid amount by the Company and will be deducted from future invoices
issued to the Company by Intrexon. 
 4.14 Termination. Notwithstanding anything herein to the contrary, this Agreement may be
terminated at any time by Intrexon (with respect to the obligations of Intrexon) or the Company, upon written notice to the other party, if the Closing shall not have occurred on or before the date that is three months from the date hereof (the
“Outside Date”); provided, however, that the right to terminate this Agreement under this Section 4.13 shall not be available to any party whose (i) breach of any provision of this Agreement, (ii) failure to comply
with their obligations under this Agreement or (iii) actions not taken in good faith, shall have been the cause of, or shall have resulted in, the failure of the Closing to occur on or prior to the Outside Date or the failure of a condition in
Section 2.3 to be satisfied at such time. 

  
 20 

 ARTICLE V 

MISCELLANEOUS 
 5.1
[Reserved]  
 5.2 Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party
shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The
Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of the Securities to Intrexon. 

5.3 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.
At or after the Closing, and without further consideration, the Company and Intrexon will execute and deliver to the other such further documents as may be reasonably requested in order to give practical effect to the intention of the parties under
the Transaction Documents. 
 5.4 Notices. Any and all notices or other communications or deliveries required or permitted to be
provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via email to the e-mail address
set forth on the signature pages attached hereto prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via email to the e-mail address set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the 2nd Trading Day following the date of
mailing, if sent by U.S. nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the
signature pages attached hereto. 
 5.5 Amendments; Waivers. No provision of this Agreement may be waived or amended except in a
written instrument signed, in the case of an amendment, by the Company and Intrexon. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a
waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. 

5.6 Headings and Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be
deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any
party. This Agreement shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement or any of the
Transaction Documents. 
 5.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and
their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Intrexon (other than by merger). Intrexon may assign any or all of its rights under this
Agreement to any Person to whom Intrexon assigns or transfers any Shares, provided such transferee agrees in writing to be bound, with respect to the transferred Shares, by the provisions of the Transaction Documents that apply to Intrexon. 

 

  
 21 

 5.8 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 

5.9 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of Florida, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in Hillsborough County, Florida. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in Hillsborough County, Florida for the
adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
serve process in any other manner permitted by law. 
 5.10 Survival. The representations and warranties contained herein shall
survive the Closing and the delivery of the Shares. 
 5.11 Execution. This Agreement may be executed in two or more counterparts, all
of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same
counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of
the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof. 

5.12 Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall
use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be
the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. 

  
 22 

 5.13 Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained
in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever Intrexon exercises a right, election, demand or option under a Transaction Document and the Company does not timely and materially perform its
related obligations within the periods therein provided, then Intrexon may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without
prejudice to its future actions and rights. 
 5.14 Replacement of Shares. If any certificate or instrument evidencing any Shares is
mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of
evidence reasonably satisfactory to the Company and the Transfer Agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless
the Company and the Transfer Agent for any losses in connection therewith or, if required by the Transfer Agent, a bond in such form and amount as is required by the Transfer Agent. The applicants for a new certificate or instrument under such
circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Shares. If a replacement certificate or instrument evidencing any Shares is requested due to a mutilation thereof, the Company may require
delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement. 
 5.15 Remedies. In
addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, Intrexon and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agrees to waive and not to assert in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate. 
 5.16 Payment Set Aside. To the extent that the Company makes a payment or
payments to Intrexon pursuant to any Transaction Document or Intrexon enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated,
declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including, without limitation, any
bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as
if such payment had not been made or such enforcement or setoff had not occurred. 
 5.17 [Reserved]. 

5.18 No Promotion. The Company agrees that it will not, and shall cause each of its Subsidiaries to not, without the prior written
consent of Intrexon, use in advertising, publicity, or otherwise the name of Intrexon, its affiliates or any of their respective partners or employees, nor 

  
 23 

 
any trade name, trademark, trade device, service mark, symbol or any abbreviation, contraction or simulation thereof owned by such persons. The Company further agrees that it shall obtain
the written consent of Intrexon prior to the Company’s or any of its Subsidiaries’ issuance of any public statement detailing the acquisition of Securities by Intrexon pursuant to this Agreement. 

5.19 Construction. The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the
Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.

 5.20 Exculpation. Intrexon acknowledges that it is not relying upon any person, firm or corporation, other than the Company and its
officers and directors (acting in their capacity as representatives of the Company), in deciding to invest and in making its investment in the Company. 

5.21 Company Acknowledgement. The Company acknowledges and agrees that (i) Intrexon is participating in the transactions
contemplated by this Agreement and the other Transaction Documents at the Company’s request and the Company has concluded that such participation is in the Company’s best interest and is consistent with the Company’s objectives and
(ii) Intrexon is acting solely in the capacity of an arm’s length purchaser. The Company further acknowledges that Intrexon is acting or has acted as an advisor, agent or fiduciary of the Company (or in any similar capacity) with respect
to this Agreement or the other Transaction Documents and any advice given by Intrexon or any of its respective representatives in connection with this Agreement or the other Transaction Documents is merely incidental to Intrexon’s acquisition
of Shares. The Company further represents to Intrexon that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 (Signature Pages Follow) 

  
 24 

 IN WITNESS WHEREOF, the parties hereto have caused this Debt Conversion Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above. 
  

							
	ORAGENICS, INC.	 		 	Address for Notice:
				
	By	 	 /s/ Alan Joslyn
	 		 	 4902 Eisenhower Blvd.
 Suite 125

Tampa, FL 33634

		 	Name: Alan Joslyn	 		 	
		 	Title: Chief Executive Officer	 		 	
			
	INTREXON CORPORATION	 		 	Address for Notice:
				
	By	 	 /s/ Donald P. Lehr
	 		 	 20374 Seneca Meadows Parkway,
 Germantown,
MD 20876

		 	Name: Donald P. Lehr	 		 	
		 	Title: Chief Legal Officer	 		 	

 [Signature page to Debt Conversion Agreement] 

 Exhibit A 

Certificate of Designation 

 Exhibit B 

Form of Legal opinion of Company Counsel 

Based upon and subject to the foregoing, it is our opinion as of this date that: 

1. Based solely upon the certificate of good standing, dated
[                 , 2017], issued by the State of Florida, the Company is a corporation validly existing and in good standing under the laws of the State of Florida.

 2. The Company has the corporate power and authority to execute, deliver and perform its obligations under the Transaction Documents,
including, without limitation, to issue and deliver the Shares as contemplated by the Agreement. Each of the Transaction Documents has been duly authorized by all necessary corporate action and each has been duly executed and delivered on behalf of
the Company, and each is a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms. 

3. The execution and delivery by the Company of the Transaction Documents, and the performance by the Company of its obligations thereunder as
of the date hereof, do not violate the Company’s Articles of Incorporation or Bylaws, do not constitute a default under or a material breach of any material agreement of the Company that has not otherwise been waived and, to our knowledge, do
not (a) violate any U. S. Federal or state statute, rule or regulation applicable to the transactions contemplated by the Transaction Documents or (b) violate any order, writ, judgment, injunction, decree, determination or award which has
been entered against the Company and of which such counsel is aware, except, with respect to clauses (a) and (b), where such violation would not materially and adversely affect the Company. 

4. The Company has the authorized capital stock as set forth in the SEC Documents. The Securities have been duly authorized, and when issued
and sold in accordance with the Securities Purchase Agreement, will be validly issued and non-assessable. 

5. No approval, authorization or other action by, or notice to or filing with, any governmental authority is required in connection with the
execution, delivery and performance by the Company of the Transaction Documents, except (a) those that have been obtained or made and are in full force and effect, and (b) any filings required by Regulation D promulgated under the
Securities Act of 1933, as amended, or by state securities laws. 
 6. To our knowledge, there is no action, proceeding or investigation
pending or overtly threatened against the Company before any court or administrative agency that questions the validity of the Transaction Documents or that could reasonably be expected to result, either individually or in the aggregate, in a
material adverse effect on the Company. 
 7. Assuming the truth and accuracy of the representations made by the Company and Intrexon in the
Debt Conversion Agreement, the sale and issuance of the Shares in conformity with the terms of the Transaction Documents constitute transactions that are exempt from the registration requirements of the Securities Act of 1933, as amended, subject to
the timely filing of a Form D pursuant to Regulation D. 

 8. The Company is not, after giving effect to the issuance of the Shares, an “investment
company” as defined in the Investment Company Act of 1940, as amended. 
 9. To our knowledge and except as set forth in the SEC
Documents with respect to Intrexon Corporation and the Koski Family Limited Partnership, there are no written contracts, agreements or understandings between the Company and any person granting such person the right (other than rights which have
been waived in writing or otherwise satisfied) to require the Company to include any securities of the Company in any registration statement. 

 Exhibit C 

Voting AgreementEX-10.6

 Exhibit 10.6 

SECOND AMENDMENT TO EXCLUSIVE CHANNEL
COLLABORATION AGREEMENT 
 This SECOND AMENDMENT TO
EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Amendment”) is effective as of November 8, 2017 (the “Second Amendment Effective Date”)
by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”) and
ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634,
U.S.A. (“Oragenics”). Intrexon on the one hand and Oragenics on the other hand may be referred to herein individually as a “Party”, and collectively as the “Parties.” 

RECITALS 

A. WHEREAS Intrexon and Oragenics are parties to that certain Exclusive Channel Collaboration Agreement,
effective June 5, 2012, as amended by that certain First Amendment to Exclusive Channel Collaboration Agreement, effective July 21, 2016 (the “Agreement”), pursuant to which Intrexon appointed Oragenics as their exclusive
channel collaborator for developing and commercializing certain products in an exclusive field as defined by the Agreement; 
 B.
WHEREAS Intrexon and Oragenics now mutually desire to further amend the Agreement; 
 D.
NOW, THEREFORE, Intrexon and Oragenics agree to amend the terms of the Agreement as provided below, effective as of the Second Amendment Effective Date. 

1. GENERALLY 
 1.1
Capitalized terms present within this Amendment that are not proper names or titles, that are not conventionally capitalized, or that are not otherwise defined within this Amendment shall have the meaning set forth in the Agreement. 

1.2 Intrexon and Oragenics, in conjunction with and contemporaneously with this Amendment, have entered into an Amendment to the Stock
Issuance Agreement of even date herewith (the “Stock Amendment”), which Stock Amendment amends the Stock Issuance Agreement by and between Intrexon and Oragenics, effective June 5, 2012 (the “Stock Agreement”).

 2. AMENDMENTS TO THE AGREEMENT 

2.1 Definitions. 
 (a)
Section 1.12 of the Agreement “Costs of Goods Sold”, Section 1.41 of the Agreement “Manufacturing Costs” and Section 1.50 of the Agreement “Product Profit” are hereby deleted in
their entirety and each replaced with “Reserved”. 

  

 (b) The following is added as a new third sentence to Section 1.14 of the Agreement
“Diligent Efforts”: 
 Oragenics’ obligation to use Diligent Efforts under this Agreement shall be deemed satisfied if
from the Second Amendment Effective Date until the end of 2018, Oragenics has budgeted one million two hundred thousand United States dollars ($1,200,000) for manufacturing and support activities related to, and including the conduct of the required
toxicology studies for the OG716 IND filing. 
 2.2 Sublicensing. The following is added as a new third sentence to the introductory
paragraph of Section 3.2 of the Agreement: 
 The parties shall agree, in connection with any such sublicense not covered under
Sections 3.2(a) through 3.2(c) below, on the applicable Sublicensing Revenue Rate (as defined herein) with respect to such sublicense. 

2.3 Milestones. Section 5.2 of the Agreement is hereby replaced in its entirety with the following Section 5.2: 

5.2 Milestones. 

(a) Oragenics Milestones. Upon the first instance of attainment of certain commercialization milestone events by an
Oragenics Product (whether such attainment is achieved by Oragenics or by a permitted sublicensee), Oragenics has agreed to pay Intrexon milestone payments as set forth in the Equity Agreement. The milestone payments are each payable in cash
(subject to Section 5.2(b)) by wire transfer to the account specified by Intrexon. The specific milestone payments due to Intrexon upon achievement of each milestone event are set forth in the Equity Agreement. 

(b) Product Sublicense Milestones. If (A) a commercialization milestone event occurs that gives rise to a right
for Intrexon to receive a payment from Oragenics under Section 5.2(a), (B) that milestone event is achieved by an Oragenics Product licensed to a Product Sublicensee under a respective Product Sublicense, and (C) Oragenics is due to
receive a milestone payment from the Product Sublicensee for achievement of that same (or substantially similar) milestone event by the sublicensed Oragenics Product under the respective Product Sublicense, then Intrexon may elect at its own
discretion to waive that particular milestone payment from Oragenics for that particular commercialization milestone 

  
 2 

 
event and instead designate the amount of the payment due to Oragenics from the Product Sublicensee for achievement of that same (or substantially similar) milestone event as Sublicensing Revenue
for which Intrexon will be entitled to receive revenue sharing under Section 5.4(b). If it so elects under this Section 5.2(b), Intrexon must notify Oragenics in writing of its waiver of that particular milestone payment and election to
share the milestone payment due from the Product Sublicensee as Sublicensing Revenue at least five (5) business days prior to the deadline for Oragenics to make a payment for the waived milestone payment. The actual receipt by Intrexon of its
full share of the Product Sublicensee milestone payment as Sublicensing Revenue will be a condition subsequent to making final any waiver of Intrexon’s rights to receive the particular milestone payment otherwise due from Oragenics under
Section 5.2(a). Oragenics will pay Intrexon any amount due under this Section 5.2(b) within the later of (i) six (6) months from underlying commercialization milestone event, or (ii) ten (10) days following the date stipulated in
the underlying Product Sublicense for Oragenics to receive the milestone payment. 
 2.4 Equity Agreement Controls. Section 5.3
of the Agreement is hereby replaced in its entirety with the following new Section 5.3: 
 5.3 Equity Agreement Controls. All
cash payments to Intrexon shall be in accordance with the terms and conditions of the Equity Agreement, which Equity Agreement shall control to the extent it may conflict with Sections 5.1 through 5.2 of this Agreement. 

2.5 Revenue Sharing. Section 5.4 of the Agreement is hereby replaced in its entirety with the following new Section 5.4: 

5.4 Revenue Sharing. 

(a) No later than thirty (30) days after each calendar quarter in which there is positive Net Sales arising from
the sale of any Oragenics Product in the Field in the Territory, Oragenics shall pay a royalty to Intrexon of ten percent (10%) of such Net Sales, on an Oragenics Product-by-Oragenics Product basis. Commencing
with the Effective Date, in the event that no Net Sales occur for a particular Oragenics Product in any calendar quarter, neither Oragenics nor Intrexon shall owe any payments hereunder with respect to such Oragenics Product. 

  
 3 

 (b) No later than thirty (30) days after each calendar quarter in
which Oragenics or any Oragenics Affiliate receives Sublicensing Revenue, Oragenics shall pay to Intrexon a percentage of such Sublicensing Revenue equal to the applicable Sublicensing Revenue Rate. “Sublicensing Revenue Rate” means
a percentage of Sublicensing Revenue applicable to a proposed sublicense by Oragenics as follows: (a) with respect to any sublicense of a Lantibiotics Oragenics Product (including new indications thereof), any revenues Oragenics receives from a
Product Sublicensee under a Product Sublicense that are not a percentage of Product Sublicensee’s Net Sales of Oragenics Products, and any amounts recovered under Section 6.3(f), the Sublicensing Revenue Rate shall be twenty five percent
(25%); and (b) with respect to any other sublicense, the Sublicensing Revenue Rate shall be determined in accordance with Section 3.2. 

2.6 Payment Reports and Records Retention. Section 5.6 of the Agreement is hereby replaced in its entirety with the following new
Section 5.6: 
 5.6 Payment Reports and Records Retention. Within thirty (30) days after the end of each calendar quarter
during which Net Sales have been generated or during which Sublicensing Revenue has been received, Oragenics shall deliver to Intrexon a written report that shall contain at a minimum for the applicable calendar quarter: 

(a) gross sales of each Oragenics Product (on a
country-by-country basis); 
 (b)
itemized calculation of Net Sales, showing all applicable deductions; 
 (c) itemized calculation of Sublicensing
Revenue, including any offsets claimed for Third Party license costs; 
 (d) the amount of the payment (if any) due
pursuant to Section 5.4(a) and/or 5.4(b); 
 (e) the amount of the payment (if any) made or made due by the
achievement of an applicable commercialization milestone event during the present calendar quarter; 
 (f) the amount
of taxes, if any, withheld to comply with any applicable law; and 
 (g) the exchange rates used in any of the
foregoing calculations. 

  
 4 

 For three (3) years after each sale or other commercial use of Oragenics Product, after
incurring any component item Oragenics incorporated into its calculation of Sublicensing Revenues, payments in accord with Section 5.2(b), or Net Sales as reported to Intrexon, Oragenics shall keep (and shall ensure that its Affiliates and, if
applicable, (sub)licensees shall keep) complete and accurate records of such sales, commercial use, or component item in sufficient detail to confirm the accuracy of the payment calculations hereunder. 

 

	3.	MISCELLANEOUS 

 3.1 Full Force and Effect. This Amendment amends
the terms of the Agreement and is deemed incorporated into the Agreement. The provisions of the Agreement as amended remain in full force and effect. 

3.2 Entire Agreement. This Amendment, together with the Agreement, the Stock Agreement, and the Stock Amendment, constitutes the entire
agreement, both written and oral, between the Parties with respect to the subject matter hereof, and any and all prior agreements with respect to the subject matter hereof, either written or oral, expressed or implied, are superseded hereby, merged
and canceled, and are null and void and of no effect. 
 3.3 Counterparts. This Amendment may be executed in one or more counterparts,
each of which will be an original and all of which together will constitute one instrument. 
 [Remainder of Page Intentionally Left
Blank; Signature Page Follows] 

  
 5 

 IN WITNESS WHEREOF, Intrexon
and Oragenics have executed this Amendment by their respective duly authorized representatives as of the Second Amendment Effective Date. 
  

							
	INTREXON CORPORATION	  	             ORAGENICS, INC.

									
					
	By:	  	 /s/ Donald P. Lehr
	  	                	  	By:	  	 /s/ Alan Joslyn

	Name:	  	Donald P. Lehr	  		  	Name:	  	Alan Joslyn
	Title:	  	Chief Legal Officer	  		  	Title:	  	Chief Executive Officer

 Signature Page to Second Amendment to Exclusive Channel Collaboration Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]